Microviable Therapeutics Closes 1.5 million Round Led by Inmunomet

Microviable Therapeutics raises capital to reach the clinical stage. The Asturian biotech in preclinical stage specialized in the development of oral drugs based on microbiota-derived products has increased capital by $1.6 million (€1.5 million), in a round led by the Madrid-based medical group Inmunomet, according to Claudio Hidalgo, CEO of Microviable Therapeutics.

Microviable Therapeutics will use the money to boost the development of its line of therapeutic products up to the clinical stage. The most advanced product, MVT-201, has been evaluated in preclinical phase with positive results and is a unique biologic based on whole gut microbiota for several indications.

Thanks to this investment, other therapeutic products will also be promoted, including the development of consortia of microorganisms customized for each disease. The resources obtained will consolidate the growth of Microviable Therapeutics, which already has international customers in more than fifteen countries for other products, in addition to an increase in its capabilities both in terms of facilities and equipment size.

Find more details about Microviable Therapeutics and read the latest business headlines of the day with our companion app. Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view.

Microviable Therapeutics emerged as a spin-off from Ipla-Csic in 2016

“We were looking for a strategic partner that would provide synergies in the clinical setting and share our vision of the use of microbiota-derived biologics for the development of new treatments,” notes the executive.

Inmunomet is a medical company specializing in intestinal intolerances and dysbiosis, with experience in the clinical setting and in the expansion phase on a national scale. Intestinal dysbiosis is a constant imbalance of the intestinal flora. There are around one hundred million bacteria of more than 300 different species, which carry out different functions that are essential for the proper functioning of the organism.

For its part, Microviable Therapeutics emerged as a spin-off from Ipla-Csic in 2016, focused on the development of technologies and therapeutic products derived from the microbiota. The technological development, together with the extensive collection of bacterial cultures, has allowed the Spanish company to generate products for purified whole microbiota and customized microbial consortia for different diseases.

Hildago holds a PhD in Biology from the University of Oviedo, where he previously obtained a BSc in Biology and a MSc in Biotechnology. He developed his PhD in the field of probiotics and microbial genetics, carrying out numerous international stays in public and private research centers, including a four-year postdoctoral stay at North Carolina State University (Raleigh, USA).

Hidalgo is accompanied by Rafael Permuy, who is responsible for business development and is a founding partner of Healthsens, Neurostech, Criogene, and Asturhealth, and Noelia Martínez, head of research and development (R&D), who holds a degree in Biology and a PhD from the University of Oviedo.

__

(Featured image by TBIT via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, sthttps://pixabay.com/photos/laboratory-care-health-medical-2821207/aff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.